Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine

被引：0
|
作者：
Bacac, Marina
Colombetti, Sara
Fahrni, Linda
Fauti, Tanja
Nicolini, Valeria
Sam, Johannes
Papastogiannidis, Petros
Le Clech, Marine
Miot, Xavier
Waldhauer, Inja
Rommel, Karolin
Gerdes, Christian
Klein, Christian
Umana, Pablo
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1594
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
    Ebert, Peter J. R.
    Cheung, Jeanne
    Yang, Yagai
    McNamara, Erin
    Hong, Rebecca
    Moskalenko, Marina
    Gould, Stephen E.
    Maecker, Heather
    Irving, Bryan A.
    Kim, Jeong M.
    Belvin, Marcia
    Mellman, Ira
    IMMUNITY, 2016, 44 (03) : 609 - 621
  • [2] Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity
    Breitbart, Eyal
    Mendel, Itzhak
    Yacov, Niva
    MOLECULAR THERAPY, 2017, 25 (05) : 270 - 271
  • [3] Combination of CEA TCB, a novel T -cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade
    Bacac, Marina
    Fauti, Tanja
    Colombetti, Sara
    Fahrni, Linda
    Nicolini, Valeria
    Gerdes, Christian
    Saro, Jose
    Karanikas, Vaios
    Klein, Christian
    Umana, Pablo
    CANCER RESEARCH, 2016, 76
  • [4] Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade
    Jiang, Yuying
    Yang, Yongbing
    Hu, Yingchao
    Yang, Rui
    Huang, Jiajia
    Liu, Yi
    Wu, Yuqing
    Li, Sheng
    Ma, Chunmei
    Humphries, Fiachra
    Wang, Bingwei
    Wang, Xi
    Hu, Zhibin
    Yang, Shuo
    CELL REPORTS, 2022, 41 (04):
  • [5] The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
    Wullschleger, Stephan
    Tichet, Melanie
    Codarri-Deak, Laura
    Umana, Pablo
    Klein, Christian
    Hanahan, Douglas
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Roller, Andreas
    Biehl, Marlene
    Fahrni, Linda
    Nicolini, Valeria
    Perro, Mario
    Nayak, Tapan
    Bommer, Esther
    Schoenle, Anne
    Karagianni, Maria
    Le Clech, Marine
    Steinhoff, Nathalie
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] PD-L1 blockade enhances anti-tumor efficacy of NK cells
    Oyer, Jeremiah L.
    Gitto, Sarah B.
    Altomare, Deborah A.
    Copik, Alicja J.
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [8] NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model
    Sola, Caroline
    Arnoux, Thomas
    Chanuc, Fabien
    Fuseri, Nicolas
    Rossi, Benjamin
    Gauthier, Laurent
    Leget, Corinne
    Bonnafous, Cecile
    Wagtmann, Nicolai
    Morel, Yannis
    Andre, Pascale
    CANCER RESEARCH, 2016, 76
  • [9] Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
    Zhang, Weinan
    He, Zhiqiang
    Liang, Fucheng
    Gong, Jie
    Tan, Liuchang
    Yang, Juan
    Song, Siji
    Xie, Luoyingzi
    Lu, Yuangang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (18) : 16763 - 16778
  • [10] Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
    Weinan Zhang
    Zhiqiang He
    Fucheng Liang
    Jie Gong
    Liuchang Tan
    Juan Yang
    Siji Song
    Luoyingzi Xie
    Yuangang Lu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16763 - 16778
12345